传奇生物CARVYKTI二线适应症在美国获批

中国地震台网自动测定：04月06日11时52分在中国台湾附近（北纬24.21度，东经121.78度）发生4.5级左右地震，最终结果以正式速报为准。（","multimedia":{"img_url":["https://n.sinaimg.cn/zhibo/408/w690h518/20240406/3408-8fe9430fa7413462048c93229ca96a70.jpg"]},"commentid":"live:finance-152-3564075:0","compere_id":0,"creator":"mingliang10@staff.sina.com.cn","mender":"mingliang10@staff.sina.com.cn","create_time":"2024-04-06 11:56:22","update_time":"2024-04-06 11:56:47","is_need_check":"0","check_time":"1970-01-01 08:00:01","check_status":"1","check_user":"","is_delete":0,"top_value":0,"is_focus":0,"source_content_id":"0","anchor_image_url":"","anchor":"直播员","ext":"{"stocks":[],"needPushWB":false,"needCMSLink":true,"needCalender":false}","old_live_cid":"0","tab":"","is_repeat":"0","tag":[{"id":"8","name":"其他"}],"like_nums":0,"comment_list":{"list":[],"total":0,"thread_show":0,"qreply":0,"qreply_show":0,"show":0},"docurl":"","rich_text_nick_to_url":[],"rich_text_nick_to_routeUri":[],"compere_info":""},{"id":3564074,"zhibo_id":152,"type":0,"rich_text":"【传奇生物CARVYKTI二线适应症在美国获批】当地时间2024年4月5日，传奇生物在美国新泽西州萨默塞特宣布，美国食品药品监督管理局（FDA）已批准CARVYKTI（西达基奥仑赛，cilta-cel）用于治疗复发或难治性多发性骨髓瘤（RRMM）患者，这些患者既往至少接受过一线治疗，包括一种蛋白酶体抑制剂（PI）和一种免疫调节剂（IMiD)且对来那度胺耐药1。CARVYKTI是首个且唯一获批用于多发性骨髓瘤患者二线治疗的B细胞成熟抗原 (BCMA) 靶向疗法，包括CAR-T疗法、双特异性抗体和抗体药物偶联物（ADC）。